Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) target bumped up to $14.00, released a report earlier today by Zacks Investment Research
- Updated: October 13, 2016
Yesterday Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded -2.31% lower at $12.58. The company’s 50-day moving average is $11.96 and its 200-day moving average is $11.03. The last stock close price is up 11.41% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 278,345 shares of the stock were exchanged, down from an average trading volume of 558,674
Indicating a possible upside of 0.11%, Zacks Investment Research increased the stock price target of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to $14.00
Previously on 10/11/2016, Barclays reported about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) raised the target price from $13.00 to $19.00. At the time, this indicated a possible upside of 0.61%.
See Chart Below
Momenta Pharmaceuticals, Inc. has a 52 week low of $7.86 and a 52 week high of $18.85 MNTA’s total market value is presently $0.
A total of 9 analysts have released a report on Momenta Pharmaceuticals, Inc.. Five analysts rating the company a strong buy, one analyst rating the company a buy, three equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $16.33.
Brief Synopsis About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.